Autolus Announces Pricing of Public Offering
February 09 2021 - 8:42PM
Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage
biopharmaceutical company developing next-generation programmed T
cell therapies, today announced the pricing of an underwritten
public offering in the United States of 14,285,715 American
Depositary Shares (“ADSs”) representing 14,285,715 ordinary shares
at a public offering price of $7.00 per ADS, for total gross
proceeds of approximately $100.0 million. All ADSs sold in the
offering were offered by Autolus. In addition, Autolus has granted
the underwriters a 30-day option to purchase up to an additional
2,142,857 ADSs at the public offering price, less underwriting
discounts and commissions. The offering is expected to close on
February 12, 2021, subject to customary closing conditions.
J.P. Morgan and Wells Fargo Securities are
acting as joint bookrunners for the offering. Kempen & Co,
Mizuho Securities and Needham & Company are acting as
co-managers.
The securities are being offered pursuant to an
effective shelf registration statement that was previously filed
with the Securities and Exchange Commission (“SEC”). A preliminary
prospectus supplement to the prospectus describing the terms of the
offering was filed with the SEC on February 8, 2021, and a final
prospectus supplement will be filed with the SEC. The offering will
be made only by means of a written prospectus and prospectus
supplement that form a part of the registration statement, which,
for the avoidance of doubt, will not constitute a "prospectus" for
the purposes of the Regulation (EU) 2017/1129 and has not been
reviewed by any competent authority in any member state in the
European Economic Area. Copies of the preliminary prospectus
supplement and the accompanying prospectus relating to the offering
may be obtained for free from either of the joint book-running
managers for the offering, J.P. Morgan Securities LLC, c/o
Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood,
NY 11717, or by telephone at +1 866 803 9204 or by email at
prospectus-eq_fi@jpmchase.com; or Wells Fargo Securities, LLC,
Attention: Equity Syndicate Department, 500 West 33rd Street, New
York, New York, 10001, at (800) 326-5897 or email a request to
cmclientsupport@wellsfargo.com.
This press release does not constitute an offer
to sell or the solicitation of an offer to buy securities, and
shall not constitute an offer, solicitation or sale in any
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of that jurisdiction.
About Autolus
Autolus is a clinical-stage biopharmaceutical
company developing next-generation, programmed T cell therapies for
the treatment of cancer. Using a broad suite of proprietary and
modular T cell programming technologies, the company is engineering
precisely targeted, controlled and highly active T cell therapies
that are designed to better recognize cancer cells, break down
their defense mechanisms and eliminate these cells. Autolus has a
pipeline of product candidates in development for the treatment of
hematological malignancies and solid tumors.
Forward-Looking Statements
This press release contains certain
forward-looking statements within the meaning of the “safe harbor”
provisions of the Private Securities Litigation Reform Act of 1995,
including statements with regard to Autolus’ expectations regarding
the completion of the proposed securities offering. Words such as
“anticipates,” "believes," “expects,” "intends," "projects," and
"future" or similar expressions are intended to identify
forward-looking statements. These forward-looking statements are
subject to the inherent uncertainties in predicting future results
and conditions and no assurance can be given that the proposed
securities offering discussed above will be consummated on the
terms described or at all. Completion of the proposed offering and
the terms thereof are subject to numerous factors, many of which
are beyond the control of Autolus, including, without limitation,
market conditions, failure of customary closing conditions and the
risk factors and other matters set forth in Autolus’ Annual Report
on Form 20-F for the year ended December 31, 2019 and other filings
Autolus makes with the SEC from time to time. Autolus undertakes no
obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise, except as may be required by law.
Contacts:
Lucinda Crabtree, Ph.D.Vice President, Investor
Relations and Corporate Communications+44 (0)7587 372
619l.crabtree@autolus.com
Julia Wilson+44 (0)7818
430877j.wilson@autolus.com
Susan A NoonanS.A. Noonan Communications, LLC+1
212 966 3650susan@sanoonan.com
Autolus Therapeutics (NASDAQ:AUTL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Autolus Therapeutics (NASDAQ:AUTL)
Historical Stock Chart
From Sep 2023 to Sep 2024